Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA P Form 4 June 14, 200	HARMACEUTIC	CALS INC									
FORM	ЛЛ									PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287			
Check this box if no longer subject to Section 16. Form 4 or				NGES IN SECUR	Estimated burden hou	Expires: January 31 2005 Estimated average burden hours per response 0.5					
Form 5 obligation may com <i>See</i> Instru- 1(b).	ons Section 17(a) of the P	ublic U		ding Cor	npany	y Act	nge Act of 1934, of 1935 or Sectio 940			
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Rasmussen Torsten			2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS					 Relationship of Reporting Person(s) to Issuer (Check all applicable) 			
		Middle) C., 3911		of Earliest Tr Day/Year)	ransaction			X Director Officer (give below)		% Owner her (specify	
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tab	la I Non I	Dorivativa	Soour	itios A		of or Bonoficio	lly Ownod	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		d Date, if	3. 4. Securit TransactionAcquired Code Disposed (Instr. 8) (Instr. 3, 4 Code V Amount		ies (A) or of (D)		Securities Beneficially Owned		7. Nature of Indirect	
Reminder: Re	port on a separate line	e for each cla	iss of secu	urities benef	icially own	ned dir	ectly c	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number Transaction Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. H Dei Sec (Ini		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 8.85	06/10/2005		А		6,500		<u>(1)</u>	06/09/2015	Common Stock	6,500	
Stock Option (Right to Buy)	\$ 8.85	06/10/2005		А		2,542		(1)	06/09/2015	Common Stock	2,542	

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
reporting o their runner runness	Director	10% Owner	Officer	Other				
Rasmussen Torsten C/O ACADIA PHARMACEUTICALS INO 3911 SORRENTO VALLEY BLVD. SAN DIEGO, CA 92121	C. X							
Signatures								
/s/ Thomas H. Aasen, Attorney-in-Fact	06/14/2005							
**Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) One-fourth of the shares subject to the Stock Option shall vest and become exercisable at the end of each 3 month period following the date of grant.
- (2) By Morgan Management ApS, a Danish corporation.
- (3) The Reporting Person has elected to convert annual retainer fees of \$7,500 into a stock option under the terms of the Issuer's Outside Director Compensation Program.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.